Aim: To review the current status of the discovery and development of new anthelmintic drugs, and to summarize recent progress in understanding how existing drugs work and how resistance to them arises.
The recent London Declaration on Neglected Tropical Diseases included statements committing signees to 'Sustain, expand and extend programmes that ensure the necessary supply of drugs and other interventions to help eradicate Guinea worm disease, and help eliminate by 2020 lymphatic filariasis....' and to 'Sustain, expand and extend drug access programmes to ensure the necessary supply of drugs and other interventions to help control by 2020 schistosomiasis, soil-transmitted helminths, ....and river blindness (onchocerciasis)'. Other important helminth diseases, such as food-borne trematodes and cysticercosis, affect tens of millions of people.
Many of these infections have been declared 'potentially eradicable' by the World Health Organisation and for some active elimination programs are under way. Except for Guinea worm, these are based on annual or more frequent mass administration of anthelmintic drugs, but there are major concerns for the implementation of these programs:
There is an increasing consensus that new drugs will be needed if the goals of the London Declaration are to be met. This meeting is designed to address these issues in a way that promotes communication between those working in the medical and veterinary fields, and that brings together academic and industrial scientists working to discover and develop novel anthelmintic drugs.
We are delighted to acknowledge sponsorships from New England Biolabs, the Burroughs Wellcome Fund, and Zoetis for financial support for this conference.
Abstracts for poster and oral presentations are invited; the deadline for submission has been extended to November 22nd 2013.
Registration fees are $175, with a discounted rate of $100 for registered students. Registration after November 15th will be subject to a 'late fee' of $50.